How to increase the butyrate-producing capacity of the gut microbiome : Do IBD patients really need butyrate replacement and butyrogenic therapy? by Sitkin, Stanislav et al.
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved.  
For permissions, please email: journals.permissions@oup.com
881
Journal of Crohn's and Colitis, 2018, 881–882
doi:10.1093/ecco-jcc/jjy033
Advance Access publication March 8, 2018
Letter to the Editor
Letter to the Editor
How to Increase the Butyrate-producing Capacity of the 
Gut Microbiome: Do IBD Patients Really Need Butyrate 
Replacement and Butyrogenic Therapy?
Stanislav Sitkin,a,b Timur Vakhitov,b Juris Pokrotnieksc,d
aDepartment of Internal Diseases, Gastroenterology and Dietetics, North-Western State Medical University named 
after I.I. Mechnikov, St Petersburg, Russia bDepartment of Microbiology, State Research Institute of Highly Pure 
Biopreparations, St Petersburg, Russia cDepartment of Internal Diseases, Rīga Stradiņš University, Riga, Latvia 
dCentre of Gastroenterology, Hepatology and Nutrition, Pauls Stradins Clinical University Hospital, Riga, Latvia
Corresponding author: Prof. Juris Pokrotnieks, MD, PhD, Pilsoņu iela 13, Rīga, LV-1002, Latvia. Tel.: +371-29245244;  
fax: +371-67614168; email: pokrot@latnet.lv
We read with great interest the paper by Laserna-Mendieta et  al. 
reporting the reduced butyrate synthesis capacity of the gut microbi-
ome in Crohn’s disease [CD] and ulcerative colitis [UC].1
Recently, we also performed a pilot comparative study of fae-
cal microbiota among patients with mild-to-moderate active UC 
[n = 37] and healthy controls [HCs; n = 38], with an emphasis on 
the genetic capacity of the microbiome to synthesise butyrate, by 
quantifying butyryl-CoA:acetate CoA-transferase [BCoAT, but] 
gene, using the same primers and technique.2 BCoAT gene content 
was significantly lower in the UC group as compared with HCs [p 
<0.05]. UC patients also had significantly lower Faecalibacterium 
prausnitzii counts than HCs, and Bacteroides thetaiotaomicron was 
detected less frequently in UC patients than in HCs. UC patients also 
were characterised by a higher Bacteroides fragilis group/F. praus-
nitzii ratio compared with HCs. No other taxa were altered between 
UC patients and HCs.
Later, 40 mild-to-moderate active left-sided UC patients were 
enrolled in an open study and randomised to receive either oral 
calcium butyrate plus inulin as a supplement to oral mesalazine 
[Group 1] or mesalazine alone [Group 2] for 28 days.3 Oral butyrate 
plus inulin significantly enhanced the faecal butyrate-producing bac-
teria [BPB] pool, evaluated as BCoAT gene content [p <0.05], signifi-
cantly reduced the elevated baseline B.  fragilis group/F. prausnitzii 
ratio, and lowered serum pro-inflammatory biomarkers in Group 1, 
while being safe and well tolerated. In Group 1, 85% of UC patients 
demonstrated significant improvement in both rectal bleeding and 
stool frequency by Day 14, compared with only 55% in Group 2 
[p <0.05].
Our results showed a significant reduction in the genetic capacity 
for butyrate synthesis by the gut microbiota in active UC patients 
as compared with controls.2 The oral butyrate plus inulin as a sup-
plement to standard treatment with mesalazine in active UC not 
only increased BCoAT gene content in faecal microbiota, but also 
improved symptoms, which meant that it was clinically relevant.3 
Previously, only one study reported that oral butyrate may improve 
the efficacy of oral mesalazine in active UC.4
Since butyrate is an important energy source for colonic epithe-
lial cells, maintains the integrity of the intestinal barrier, and exerts 
anti-inflammatory effects,5 we believe that it is useful both to redress 
the butyrate deficiency, and to restore the BPB pool, at least in patients 
with active disease. Dietary fibre also can be effective in inflammatory 
bowel disease [IBD], but it should most likely be used in an inactive 
disease because of possible side effects. Larger studies will be required 
to assess the efficacy of oral butyrate and usefulness of dietary fibre in 
IBD. The disease activity and BCoAT gene level should be considered.
Finally, the present data support the usefulness of BCoAT gene 
content determination as a valuable biomarker to assess gut micro-
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